ZA200509508B - Composition for improving cognition and memory - Google Patents

Composition for improving cognition and memory

Info

Publication number
ZA200509508B
ZA200509508B ZA200509508A ZA200509508A ZA200509508B ZA 200509508 B ZA200509508 B ZA 200509508B ZA 200509508 A ZA200509508 A ZA 200509508A ZA 200509508 A ZA200509508 A ZA 200509508A ZA 200509508 B ZA200509508 B ZA 200509508B
Authority
ZA
South Africa
Prior art keywords
memory
composition
improving cognition
cognition
improving
Prior art date
Application number
ZA200509508A
Other languages
English (en)
Inventor
Laudon Moshe
Zisapel Nava
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of ZA200509508B publication Critical patent/ZA200509508B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200509508A 2003-04-29 2006-11-24 Composition for improving cognition and memory ZA200509508B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment

Publications (1)

Publication Number Publication Date
ZA200509508B true ZA200509508B (en) 2006-11-29

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509508A ZA200509508B (en) 2003-04-29 2006-11-24 Composition for improving cognition and memory

Country Status (29)

Country Link
US (2) US8859593B2 (ru)
EP (1) EP1620058B1 (ru)
JP (2) JP4981440B2 (ru)
KR (1) KR101136885B1 (ru)
CN (1) CN1787820B (ru)
AR (1) AR048370A1 (ru)
AT (1) ATE539746T1 (ru)
BR (1) BRPI0409935A (ru)
CA (1) CA2521182C (ru)
CL (1) CL2004000877A1 (ru)
CY (1) CY1112689T1 (ru)
DK (1) DK1620058T3 (ru)
EA (1) EA008768B1 (ru)
ES (1) ES2380364T3 (ru)
HK (1) HK1087635A1 (ru)
IL (1) IL155666A (ru)
IS (1) IS8090A (ru)
MX (1) MXPA05011590A (ru)
NO (1) NO333015B1 (ru)
NZ (1) NZ542724A (ru)
PE (1) PE20050144A1 (ru)
PL (1) PL1620058T3 (ru)
PT (1) PT1620058E (ru)
SI (1) SI1620058T1 (ru)
TW (1) TWI340037B (ru)
UA (1) UA87980C2 (ru)
UY (1) UY28296A1 (ru)
WO (1) WO2004096118A2 (ru)
ZA (1) ZA200509508B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
AU2013211880A1 (en) 2012-01-26 2014-08-21 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
JP6144358B2 (ja) * 2012-12-18 2017-06-07 ヴァンダ ファーマシューティカルズ インコーポレイテッド 概日リズム障害の治療
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
ES2738633T3 (es) * 2015-02-04 2020-01-24 Soeur Josefa Menendez Sistema terapéutico transdérmico que contiene valentonina y su uso como medicamento
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) * 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4765985A (en) 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
EP0249343B1 (en) 1986-06-13 1992-01-08 Alza Corporation Moisture activation of transdermal drug delivery system
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
NZ244760A (en) 1991-10-18 1997-02-24 Alza Corp Transdermal administration of melatonin; device comprising melatonin with skin permeation enhancer and melatonin impermeable backing on skin-distal device surface
CA2127450C (en) * 1992-01-07 2007-04-17 Samuel Wadsworth Transgenic animal models for alzheimer's disease
ES2090861T3 (es) 1992-04-07 1996-10-16 Neurim Pharma 1991 Utilizacion de melatonina para la preparacion de un medicamento para el tratamiento de la hiperplasia de prostata benigna.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
AU7323794A (en) 1993-07-09 1995-02-06 Cygnus Therapeutic Systems Method and device for providing nicotine replacement therapy transdermally/transbuccally
CA2187023A1 (en) 1994-04-13 1995-10-26 Steven Andrew Giannos Temporally controlled drug delivery systems
US5872101A (en) 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
MD1716C2 (ru) 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Применение мелатонина для лечения пациентов с бензодиазепиновой зависимостью
US5696115A (en) 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
DK0906089T3 (da) 1996-05-13 2003-12-08 Novartis Consumer Health Sa Mundafgivelsessystem
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
ZA984637B (en) * 1997-05-30 1998-12-21 Neurosearch As Spiro-quinuclidine derivatives their preparation and use
US6274615B1 (en) * 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
AU5787999A (en) * 1998-08-26 2000-03-21 Andrei Zakharovich Afanasiev Method for treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
DE60006069T2 (de) 1999-02-05 2004-07-29 Cipla Ltd. Topische sprays enthaltend eine filmbildende zusammensetzung
US6353051B1 (en) 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
BR0016918A (pt) 2000-01-05 2004-03-23 Neurim Pharma 1991 Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas
EP2138177A1 (en) * 2000-03-03 2009-12-30 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
DE10013712A1 (de) 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
MXPA03008762A (es) 2001-03-26 2004-02-18 Smithkline Beecham Corp Forma de dosificacion oral que contiene nicotina.
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
EP1304048B1 (en) * 2001-10-22 2004-09-22 Ivo Pera Composition to reduce or quit smoking addiction
US7113651B2 (en) 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
WO2004096118A3 (en) 2005-10-13
EP1620058B1 (en) 2012-01-04
KR20060005402A (ko) 2006-01-17
IL155666A (en) 2013-12-31
CN1787820B (zh) 2010-05-05
IL155666A0 (en) 2004-09-27
NZ542724A (en) 2007-05-31
TWI340037B (en) 2011-04-11
HK1087635A1 (en) 2006-10-20
JP4981440B2 (ja) 2012-07-18
PL1620058T3 (pl) 2012-07-31
EA008768B1 (ru) 2007-08-31
WO2004096118A2 (en) 2004-11-11
CL2004000877A1 (es) 2005-01-07
ATE539746T1 (de) 2012-01-15
WO2004096118B1 (en) 2005-12-01
JP2012116859A (ja) 2012-06-21
EP1620058A2 (en) 2006-02-01
MXPA05011590A (es) 2006-03-08
KR101136885B1 (ko) 2012-04-20
BRPI0409935A (pt) 2006-04-25
EP1620058A4 (en) 2006-07-26
CA2521182C (en) 2011-05-31
PT1620058E (pt) 2012-04-13
ES2380364T3 (es) 2012-05-11
JP2006525317A (ja) 2006-11-09
IS8090A (is) 2005-10-25
PE20050144A1 (es) 2005-05-12
CN1787820A (zh) 2006-06-14
CA2521182A1 (en) 2004-11-11
UY28296A1 (es) 2004-11-30
US8859593B2 (en) 2014-10-14
UA87980C2 (ru) 2009-09-10
EA200501666A1 (ru) 2006-06-30
NO20055531L (no) 2005-11-23
CY1112689T1 (el) 2016-02-10
DK1620058T3 (da) 2012-05-07
US20060229340A1 (en) 2006-10-12
TW200501948A (en) 2005-01-16
US20140378512A1 (en) 2014-12-25
NO333015B1 (no) 2013-02-18
AR048370A1 (es) 2006-04-26
SI1620058T1 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
ZA200509508B (en) Composition for improving cognition and memory
AP2089A (en) Compositions and methods for combination antiviraltherapy
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
AU2003256805A8 (en) Compounds compositions and methods
GB0203421D0 (en) Composition
EP1684771A4 (en) COMPOSITION AND METHOD
GB0208608D0 (en) Composition
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
GB0218241D0 (en) Composition
EP1495751A4 (en) hair dye
GB0203528D0 (en) Process and composition
GB0213767D0 (en) Composition
GB0203616D0 (en) Composition
GB0303581D0 (en) Process and composition
GB0325238D0 (en) Composition and use
GB0311163D0 (en) Composition and use
GB0325241D0 (en) Composition and use
GB0301401D0 (en) Composition and use
GB0311167D0 (en) Composition and use
GB0311164D0 (en) Composition and use
GB0311166D0 (en) Composition and use
GB0326699D0 (en) Method and composition
GB0225783D0 (en) Composition and process